Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2022

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Form TR-1 BE - PART I

  • Read more about Form TR-1 BE - PART I

S.F.P.I/F.P.I.M

  • Read more about S.F.P.I/F.P.I.M

Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation

  • Read more about Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation

Bone Therapeutics provides Third Quarter 2022 Business Update

  • Read more about Bone Therapeutics provides Third Quarter 2022 Business Update

Transparency notification received from S.F.P.I/F.P.I.M

  • Read more about Transparency notification received from S.F.P.I/F.P.I.M

Extraordinary General Meeting

  • Read more about Extraordinary General Meeting

Bone Therapeutics to regain worldwide rights to ALLOB

  • Read more about Bone Therapeutics to regain worldwide rights to ALLOB

Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022

  • Read more about Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022

Bone Therapeutics: Information on the total number of voting rights and shares

  • Read more about Bone Therapeutics: Information on the total number of voting rights and shares

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2022
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions